BDSX News and Press, Biodesix Inc. From 11/10/22

Data confirms the ability of the VeriStrat ® test to predict outcomes in patients with Non-small Cell Lung Cancer treated with immunotherapy regimens Biodesix, Inc . (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease,...

Biodesix, Inc. (BDSX) Q3 2022 Earnings Conference Call November 3, 2022 08:00 a.m. ET Company Representatives Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Chris Brinzey - Investor Relations Conference Call Participants...

Biodesix press release ( NASDAQ: BDSX ): Q3 GAAP EPS of -$0.34 misses by $0.01 . Revenue of $11.11M (+70.1% Y/Y) beats by $0.94M . Cash and cash equivalents of $15.2 million as of September 30, 2022 For further details see: Biodesix GAAP EPS of -$0.34...

Third quarter 2022 core Lung Diagnostic revenue of $9.2 million increased 102% over the comparable period in 2021; U.S. Federal Supply Schedule Contract expands coverage to Veterans Health Administration and Military Health System Medical Centers for its entire Lung Diagnostic...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the third quarter ended September 30, 2022 before the open of trading on Thursday, November 3. Biodesix’s...

Summary Today, we circle back on small diagnostic firm Biodesix, Inc. for the first time since summer of last year. This stock is down some 80% over the past year, but management recently provided preliminary third quarter guidance that exceeded expectations. An investment ana...

Expands Coverage to Veterans Health Administration and Military Health System Medical Centers for Its Entire Lung Diagnostic Portfolio Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the awar...

New data reinforces the performance of the Nodify XL2® proteomic test in assessing risk of malignancy of pulmonary nodules in different patient populations Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, an...

Biodesix ( NASDAQ: BDSX ) expects 3Q22 total revenue to be in the range of $10.6M to $11.2M, representing growth of 62% to 71% Y/Y vs consensus of $10.07M . 3Q22 core lung diagnostic testing revenues growth up 96% to 103% compared to 3Q21. Total quarterly lung diag...

Third quarter 2022 core lung diagnostic testing revenues growth up 96% to 103% compared to third quarter 2021 Biodesix, Inc. (NASDAQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report th...